Medpace Holdings Management
Management Kriterienprüfungen 4/4
Medpace Holdings' CEO ist August Troendle , ernannt in Jul 1992, hat eine Amtszeit von 31.92 Jahren. Die jährliche Gesamtvergütung beträgt $1.65M , bestehend aus 49.5% Gehalt und 50.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 17.43% der Aktien des Unternehmens, im Wert von $2.13B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.3 Jahre bzw. 5.8 Jahre.
Wichtige Informationen
August Troendle
Geschäftsführender
US$1.6m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 49.5% |
| Amtszeit als Geschäftsführer | 31.9yrs |
| Eigentum des Geschäftsführers | 17.4% |
| Durchschnittliche Amtszeit des Managements | 5.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 5.8yrs |
Jüngste Management Updates
Recent updates
What You Can Learn From Medpace Holdings, Inc.'s (NASDAQ:MEDP) P/E
Jun 18
Medpace: Clear Winner If China Blockade Succeeds
Jun 04A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
May 22Does Medpace Holdings (NASDAQ:MEDP) Deserve A Spot On Your Watchlist?
Apr 12Medpace: Exceptional Performance, Almost Fully Priced In
Mar 11Medpace Holdings, Inc.'s (NASDAQ:MEDP) 32% Jump Shows Its Popularity With Investors
Feb 18Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Feb 09A Look At The Intrinsic Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
Jan 25Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?
Jan 10Shareholders Should Be Pleased With Medpace Holdings, Inc.'s (NASDAQ:MEDP) Price
Dec 26Should You Investigate Medpace Holdings, Inc. (NASDAQ:MEDP) At US$275?
Nov 08Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 29% Below Their Intrinsic Value Estimate
Oct 23If EPS Growth Is Important To You, Medpace Holdings (NASDAQ:MEDP) Presents An Opportunity
Oct 10Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?
Aug 27Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Jul 31A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
Jul 18Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today
Jul 04Is Medpace Holdings (NASDAQ:MEDP) A Risky Investment?
May 25Is Now The Time To Look At Buying Medpace Holdings, Inc. (NASDAQ:MEDP)?
Apr 27An Intrinsic Calculation For Medpace Holdings, Inc. (NASDAQ:MEDP) Suggests It's 28% Undervalued
Apr 12We Ran A Stock Scan For Earnings Growth And Medpace Holdings (NASDAQ:MEDP) Passed With Ease
Mar 27Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?
Feb 14What Is Medpace Holdings, Inc.'s (NASDAQ:MEDP) Share Price Doing?
Jan 16Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 41% Below Their Intrinsic Value Estimate
Jan 03Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today
Dec 20Medpace Holdings (NASDAQ:MEDP) Has A Rock Solid Balance Sheet
Nov 16Growth Investors: Industry Analysts Just Upgraded Their Medpace Holdings, Inc. (NASDAQ:MEDP) Revenue Forecasts By 13%
Nov 03Why Medpace Holdings, Inc. (NASDAQ:MEDP) Could Be Worth Watching
Oct 10Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 33% Below Their Intrinsic Value Estimate
Sep 26Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?
Aug 28We Think Medpace Holdings (NASDAQ:MEDP) Can Manage Its Debt With Ease
Aug 01Medpace 2022 revenue guidance above consensus estimate as Q2 beats on top, bottom lines
Jul 25Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$312m |
| Dec 31 2023 | US$2m | US$814k | US$283m |
| Sep 30 2023 | n/a | n/a | US$273m |
| Jun 30 2023 | n/a | n/a | US$268m |
| Mar 31 2023 | n/a | n/a | US$257m |
| Dec 31 2022 | US$2m | US$770k | US$245m |
| Sep 30 2022 | n/a | n/a | US$227m |
| Jun 30 2022 | n/a | n/a | US$209m |
| Mar 31 2022 | n/a | n/a | US$199m |
| Dec 31 2021 | US$6m | US$697k | US$181m |
| Sep 30 2021 | n/a | n/a | US$182m |
| Jun 30 2021 | n/a | n/a | US$175m |
| Mar 31 2021 | n/a | n/a | US$159m |
| Dec 31 2020 | US$4m | US$608k | US$145m |
| Sep 30 2020 | n/a | n/a | US$124m |
| Jun 30 2020 | n/a | n/a | US$107m |
| Mar 31 2020 | n/a | n/a | US$110m |
| Dec 31 2019 | US$8m | US$504k | US$100m |
| Sep 30 2019 | n/a | n/a | US$93m |
| Jun 30 2019 | n/a | n/a | US$88m |
| Mar 31 2019 | n/a | n/a | US$78m |
| Dec 31 2018 | US$528k | US$420k | US$73m |
| Sep 30 2018 | n/a | n/a | US$61m |
| Jun 30 2018 | n/a | n/a | US$52m |
| Mar 31 2018 | n/a | n/a | US$45m |
| Dec 31 2017 | US$598k | US$419k | US$39m |
Vergütung im Vergleich zum Markt: AugustDie Gesamtvergütung ($USD1.65M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD13.53M).
Entschädigung vs. Einkommen: AugustDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
August Troendle (68 yo)
31.9yrs
Amtszeit
US$1,646,031
Vergütung
Dr. August James Troendle, M.D. serves as Chairman of CinRx Pharma, LLC. He has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman & CEO | 31.9yrs | US$1.65m | 17.43% $ 2.2b | |
| President | 2.8yrs | US$945.08k | 0.070% $ 8.7m | |
| CFO & Treasurer | 5.3yrs | US$690.48k | 0.019% $ 2.4m | |
| Executive Vice President of Operations | 7.4yrs | US$1.12m | 0.024% $ 3.0m | |
| Chief Compliance Officer | 12yrs | US$914.64k | 0.043% $ 5.4m | |
| Chief Information Officer | 3.4yrs | keine Daten | keine Daten | |
| Associate Director of Investors Relations | no data | keine Daten | keine Daten | |
| Vice President of Business Development & Marketing | no data | keine Daten | keine Daten | |
| Senior Vice President of Commercial Operations & Clinical Pharmacology Unit | no data | keine Daten | keine Daten | |
| Chief Medical Officer of Medical Department | 1.4yrs | keine Daten | keine Daten | |
| Senior Vice President of Clinical Monitoring | no data | keine Daten | keine Daten |
5.3yrs
Durchschnittliche Betriebszugehörigkeit
58yo
Durchschnittliches Alter
Erfahrenes Management: MEDPDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.3 ).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman & CEO | 31.9yrs | US$1.65m | 17.43% $ 2.2b | |
| Lead Independent Director | 5.8yrs | US$264.98k | 0.0065% $ 806.0k | |
| Independent Director | 5.8yrs | US$217.48k | 0.017% $ 2.1m | |
| Independent Director | 7.9yrs | US$227.35k | 0.0014% $ 180.6k | |
| Independent Director | 7.9yrs | US$234.97k | 0.070% $ 8.7m | |
| Independent Director | 1.4yrs | US$258.37k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$209.98k | 0.00081% $ 100.9k |
5.8yrs
Durchschnittliche Betriebszugehörigkeit
64yo
Durchschnittliches Alter
Erfahrener Vorstand: MEDPDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).